Australia’s largest vitamins company, now owned by Japanese group Kirin, is buying into the fast-growing world of gut-based medical treatments as consumer demand shifts from traditional supplements to more targeted, science-backed products. The business it is backing focuses on therapies built from microorganisms naturally found in the human gut, an area that has attracted rising interest from both investors and health brands looking for the next wave of wellness innovation.
Under the deal, Blackmores is taking a 14% stake in Adelaide biotech BiomeBank, in a transaction that values the specialist probiotics group at around $60 million. Other backers already on the register include a fund managed by Ellerston Capital and the South Australian Venture Capital Fund, run by Artesian Venture Partners. While probiotics rely on live bacteria and yeasts to support digestion, immune function and overall gut health, the category remains relatively small compared with traditional vitamins, which are estimated to be about 20 times larger by market size.
This move looks like part of a broader shift in the supplements industry, where large vitamin brands are starting to hedge their bets by moving into more niche, medically oriented products. If the probiotics market continues to expand from its current $7 billion base, Blackmores’ early position in an emerging gut-microbiome player could open new revenue streams and product lines. At the same time, integrating advanced biotech into a consumer-focused portfolio seems likely to test how quickly mainstream customers adopt these more complex treatments, and how regulators respond as the science evolves.
